FTH
NASDAQ HealthcareFaeth Therapeutics, Inc. - Common Stock
Biotechnology
Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. The company was formerly known as Sensei Biotherapeutics, Inc. and changed its name to Faeth Therapeutics, Inc. in June 2026. The company was incorporated in 1999 and is headquartered in Rockville, Maryland.
๐ Market Data
| Price | $25.94 |
|---|---|
| Volume | 662,906 |
| Market Cap | 668.70M |
| Beta | -0.260 |
| RSI (14-Day) | 52.2 |
| 200-Day MA | $18.04 |
| 50-Day MA | $21.11 |
| 52-Week High | $37.90 |
| 52-Week Low | $6.33 |
| Price / Book | -0.25 |
๐ฏ Investment Strategy Scores
FTH scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ฐ Dividend Daddy (49/100) โ this strategy High dividend yield + low volatility.
Lowest fit among scored strategies: ๐ Moon Shot (3/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find FTH in your text
Paste any article, transcript, or post โ the tool will extract FTH and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-07-16.